Abstract:Background: The treatment of lung adenocarcinoma (LUAD) has been stuck in a bottleneck due to a number of factors. There is a pressing need for research into potential genetic markers to help drug development and improve the prognosis of patients. SLC2A1 has been reported in multiple LUAD-related prognosis prediction signatures. However, the role of SLC2A1 in the occurrence and development of WAD and its impact on prognosis remain elusive. Methods: The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) were used to acquire the samples. We used R to perform statistical analysis, Gene Set Enrichment Analysis (GSEA), immune infiltration and immune cell correlation analysis, drug sensitivity analysis, and visualization. The immune cell score was calculated using the Timer2.0 database. Prognostic analysis was performed using R, Gene Expression Profiling Interactive Analysis (GEPIA), and the Kaplan-Meier Plotter. Overall survival and progression free survival were the main outcome of prognosis analysis. Protein-protein interaction, disease-genetics analysis, and tissue-specific enrichment analyses were performed using Metascape. Results: SLC2A1 was highly expressed in LUAD tissues. Univariate COX regression [hazard ratio (HR) = 1.689, 95% confidence interval (CI): 1.242-2.249, P<0.001] and multivariate COX regression including age, gender, smoking, TNM stage and SLC2A1 expression (HR = 1.567, 95% CI: 1.127-2.179, P=0.008) showed that SLC2A1 was an independent prognostic risk factor for LUAD. GSEA and Metascape analysis showed that SLC2A1 was strongly associated with the cell cycle, mitosis, lung tissue, and tumor recurrence. Immune correlation analysis showed that SLC2A1 was associated with two tumor infiltration immune cells: activated CD (cluster of differentiation)4* memory T cells (r=0.31, P=0.003) and activated mast cells (r=-0.28, P=0.010). Moreover, patients with high SLC2A1 expression had higher immune checkpoint molecules and Tumor Immune Dysfunction and Exclusion (TIDE) scores, indicating poorer immunotherapy efficacy. Patients with high SLC2A1 expression were more sensitive to chemotherapy drugs and less sensitive to targeted drugs compared to those with low SLC2A1 expression. Conclusions: The high expression of SLC2A1 in LUAD predicted poor prognosis and was closely related to tumor immunity, which could be used as an effective prognostic biomarker to provide a new strategy for clinical prognosis assessment and immunotherapy for LUAD.

GREB1L Overexpression Correlates with Prognosis and Immune Cell Infiltration in Lung Adenocarcinoma.

GREB1L overexpression is associated with good clinical outcomes in breast cancer

GREB1L overexpression associates with good clinical outcomes in breast cancer

PLAU and GREM1 are prognostic biomarkers for predicting immune response in lung adenocarcinoma

Loss of LIMCH1 Predicts Poor Prognosis in Patients with Surgically Resected Lung Adenocarcinoma: A Study Based on Immunohistochemical Analysis and Bioinformatics

GBE1 Is an Independent Prognostic Marker and Associated With CD163+ Tumor-Associated Macrophage Infiltration in Lung Adenocarcinoma

Integrated Bioinformatics Analysis Reveals Correlations of High TRIM59 Expression with Worse Prognosis and Immune Infiltrates in Lung Adenocarcinoma

SLC2A1 Plays a Significant Prognostic Role in Lung Adenocarcinoma and is Associated with Tumor Immunity Based on Bioinformatics Analysis.

GRAP2 is a Prognostic Biomarker and Correlated with Immune Infiltration in Lung Adenocarcinoma.

Bioinformatics Analysis and Experimental Study of Exonuclease 1 Gene in Lung Adenocarcinoma

Identification of Pivotal Genes with Prognostic Evaluation Value in Lung Adenocarcinoma by Bioinformatics Analysis

Prognostic value of SEC61G in lung adenocarcinoma: a comprehensive study based on bioinformatics and in vitro validation

The prognostic value of bioinformatics analysis of ECM receptor signaling pathways and LAMB1 identification as a promising prognostic biomarker of lung adenocarcinoma

Analysis of Genes Associated with Prognosis of Lung Adenocarcinoma Based on GEO and TCGA Databases.

KLRB1 expression is associated with lung adenocarcinoma prognosis and immune infiltration and regulates lung adenocarcinoma cell proliferation and metastasis through the MAPK/ERK pathway

ADGRD1 as a Potential Prognostic and Immunological Biomarker in Non-Small-Cell Lung Cancer

Identification of small proline‐rich protein 1B ( SPRR1B ) as a prognostically predictive biomarker for lung adenocarcinoma by integrative bioinformatic analysis

Bioinformatics and integrated analyses of prognosis-associated key genes in lung adenocarcinoma

Exonuclease 1 (EXO1) is a Potential Prognostic Biomarker and Correlates with Immune Infiltrates in Lung Adenocarcinoma

Exploring the function and prognostic value of RPLP0, RPLP1 and RPLP2 expression in lung adenocarcinoma

GALNT2/14 Overexpression Correlate with Prognosis and Methylation: Potential Therapeutic Targets for Lung Adenocarcinoma.